ENSC - CIK 0001716947
The table below shows Ensysce Biosciences, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$3.50M | -$1.71M | -$3.41M | -$3.61M | -$3.44M | -$517.15K |
| Capital expenditure | - | - | - | - | - | - |
| Investing cash flow | - | - | - | - | $4.50K | -$62.50K |
| Dividends paid | - | - | - | - | - |
Ensysce Biosciences, Inc. reported operating cash flow of -$7.81M for fiscal year 2025. That is down 4.0% from -$7.50M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow declined from -$1.24M (FY 2018) to -$7.81M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | -$63.95K | $1.26M | $5.69M | $1.87M | -$391.27K | $612.86K |